Jeffrey M. Vainshtein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeffrey M. Vainshtein has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Avraham Eisbruch
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States
3 shared publicationsCarol R. Bradford
Department of Otolaryngology - Head and Neck Surgery, University of Michigan, Ann Arbor, MI, United States
3 shared publicationsDouglas B. Chepeha
Department of Otolaryngology - Head and Neck Surgery, University of Michigan, Ann Arbor, MI, United States
3 shared publicationsFrancis P. Worden
Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States
3 shared publicationsGregory T. Wolf
Department of Otolaryngology - Head and Neck Surgery, University of Michigan, Ann Arbor, MI, United States
3 shared publicationsJonathan B. McHugh
Department of Pathology, University of Michigan, Ann Arbor, MI, United States
3 shared publications
Latest Publications
- 1 March 2014
- Published by Elsevier in Oral Oncology
- Vol. 50 (3) , 234-239
Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer
- 1 March 2014
- Published by Elsevier in Oral Oncology
- Vol. 50 (3) , 234-239
Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer
- 7 November 2013
- Published by Wiley in Head & Neck
- Vol. 37 (1) , 8-11
Human papillomavirus–related oropharyngeal cancer: HPV and p16 status in the recurrent versus parent tumor
Background: Although typically associated with a favorable prognosis, a minority of human papillomavirus (HPV)‐related (+) oropharyngeal cancers recur after chemoradiation. We postulated that a minor HPV‐negative tumor subfraction may be responsible for recurrences of HPV+ oropharyngeal cancer.Methods: Paired untreated primary and recurrent tumor specimens were identified for 37 patients with oropharyngeal cancer who received definitive chemoradiotherapy at our institution. Concordance in HPV/p16 expression between primary and recurrent tumors was assessed.Results: Among 31 patients with HPV+/p16+ primary tumors, 30 (97%) retained evidence of both HPV and p16 expression at recurrence (27 HPV+/p16+; 3 HPV+/p16‐partial). One (3%) initially HPV+/p16+ patient developed an HPV‐negative/p16‐negative lung squamous cell carcinoma (SCC), representing either a discordant oropharyngeal cancer metastasis or second primary tumor.Conclusion: HPV‐related oropharyngeal cancers retain HPV+/p16+ expression at recurrence. Our results fail to provide evidence that a minor HPV‐negative tumor subfraction is responsible for biologically aggressive behavior of HPV+ oropharyngeal cancer that recurs after chemoradiation. © 2014 Wiley Periodicals, Inc. Head Neck 37: 8–11, 2015
- 7 November 2013
- Published by Wiley in Head & Neck
- Vol. 37 (1) , 8-11
Human papillomavirus–related oropharyngeal cancer: HPV and p16 status in the recurrent versus parent tumor
Background: Although typically associated with a favorable prognosis, a minority of human papillomavirus (HPV)‐related (+) oropharyngeal cancers recur after chemoradiation. We postulated that a minor HPV‐negative tumor subfraction may be responsible for recurrences of HPV+ oropharyngeal cancer.Methods: Paired untreated primary and recurrent tumor specimens were identified for 37 patients with oropharyngeal cancer who received definitive chemoradiotherapy at our institution. Concordance in HPV/p16 expression between primary and recurrent tumors was assessed.Results: Among 31 patients with HPV+/p16+ primary tumors, 30 (97%) retained evidence of both HPV and p16 expression at recurrence (27 HPV+/p16+; 3 HPV+/p16‐partial). One (3%) initially HPV+/p16+ patient developed an HPV‐negative/p16‐negative lung squamous cell carcinoma (SCC), representing either a discordant oropharyngeal cancer metastasis or second primary tumor.Conclusion: HPV‐related oropharyngeal cancers retain HPV+/p16+ expression at recurrence. Our results fail to provide evidence that a minor HPV‐negative tumor subfraction is responsible for biologically aggressive behavior of HPV+ oropharyngeal cancer that recurs after chemoradiation. © 2014 Wiley Periodicals, Inc. Head Neck 37: 8–11, 2015
- 30 August 2013
- Published by Wiley in Head & Neck
- Vol. 36 (11) , 1589-1595
Head and neck squamous cell carcinoma of unknown primary: Neck dissection and radiotherapy or definitive radiotherapy
Background: Management of head and neck carcinoma from unknown primary (HNCUP) remains controversial, with neck dissection and radiotherapy (RT) or definitive RT both commonly used. The purpose of this study was to characterize HNCUP and retrospectively compare outcomes for patients treated with neck dissection + RT versus definitive RT.Methods: From 1994 to 2009, 41 patients with HNCUP underwent either neck dissection + RT (n = 22) or definitive RT ± concurrent chemotherapy (n = 19) at our institution. Treatment outcomes were compared using Kaplan–Meier methods and log‐rank test.Results: There were no differences between patients treated with neck dissection + RT and definitive RT in overall survival (OS), progression‐free survival (PFS), locoregional relapse‐free survival (LRFS), freedom from locoregional failure (FFLRG), or freedom from distant failure (FFDF). Among 17 patients who underwent neck dissection + RT for whom human papillomavirus (HPV) status could be determined, HPV(+) patients trended toward improved OS (p = .06) and PFS (p = .15).Conclusion: Neck dissection and postoperative RT resulted in similar outcomes as definitive RT. The prognostic implications of HPV(+) nodes in HNCUP are similar to those in oropharyngeal primary cancers. © 2013 Wiley Periodicals, Inc. Head Neck 36: 1589–1595, 2014
- 30 August 2013
- Published by Wiley in Head & Neck
- Vol. 36 (11) , 1589-1595
Head and neck squamous cell carcinoma of unknown primary: Neck dissection and radiotherapy or definitive radiotherapy
Background: Management of head and neck carcinoma from unknown primary (HNCUP) remains controversial, with neck dissection and radiotherapy (RT) or definitive RT both commonly used. The purpose of this study was to characterize HNCUP and retrospectively compare outcomes for patients treated with neck dissection + RT versus definitive RT.Methods: From 1994 to 2009, 41 patients with HNCUP underwent either neck dissection + RT (n = 22) or definitive RT ± concurrent chemotherapy (n = 19) at our institution. Treatment outcomes were compared using Kaplan–Meier methods and log‐rank test.Results: There were no differences between patients treated with neck dissection + RT and definitive RT in overall survival (OS), progression‐free survival (PFS), locoregional relapse‐free survival (LRFS), freedom from locoregional failure (FFLRG), or freedom from distant failure (FFDF). Among 17 patients who underwent neck dissection + RT for whom human papillomavirus (HPV) status could be determined, HPV(+) patients trended toward improved OS (p = .06) and PFS (p = .15).Conclusion: Neck dissection and postoperative RT resulted in similar outcomes as definitive RT. The prognostic implications of HPV(+) nodes in HNCUP are similar to those in oropharyngeal primary cancers. © 2013 Wiley Periodicals, Inc. Head Neck 36: 1589–1595, 2014
- 1 May 2013
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 86 (1) , 96-101
Prognostic Significance of Carbohydrate Antigen 19-9 in Unresectable Locally Advanced Pancreatic Cancer Treated With Dose-Escalated Intensity Modulated Radiation Therapy and Concurrent Full-Dose Gemcitabine: Analysis of a Prospective Phase 1/2 Dose Escalation Study
- 1 May 2013
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 86 (1) , 96-101
Prognostic Significance of Carbohydrate Antigen 19-9 in Unresectable Locally Advanced Pancreatic Cancer Treated With Dose-Escalated Intensity Modulated Radiation Therapy and Concurrent Full-Dose Gemcitabine: Analysis of a Prospective Phase 1/2 Dose Escalation Study
- Open Access
- 9 June 2012
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 82
Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy
Low-risk prostate cancer (PCa) patients have excellent outcomes, with treatment modality often selected by perceived effects on quality of life. Acute urinary symptoms are common during external beam radiotherapy (EBRT), while chronic symptoms have been linked to urethral dose. Since most low-risk PCa occurs in the peripheral zone (PZ), we hypothesized that EBRT using urethral sparing intensity modulated radiation therapy (US-IMRT) could improve urinary health-related quality of life (HRQOL) while maintaining high rates of PCa control.
- 9 June 2012
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 82
Open AccessRandomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy
Low-risk prostate cancer (PCa) patients have excellent outcomes, with treatment modality often selected by perceived effects on quality of life. Acute urinary symptoms are common during external beam radiotherapy (EBRT), while chronic symptoms have been linked to urethral dose. Since most low-risk PCa occurs in the peripheral zone (PZ), we hypothesized that EBRT using urethral sparing intensity modulated radiation therapy (US-IMRT) could improve urinary health-related quality of life (HRQOL) while maintaining high rates of PCa control.